INTRODUCTION
Hodgkin Lymphoma is a lymphoid malignancy with an annual incidence of 2-3 per 100 000 in Western countries. At first diagnosis, more than 80% of patients with Hodgkin Lymphoma can be cured with modern combined modality therapy. However, a small proportion of patients is primary refractory to the treatment or will subsequently relapse. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has become the standard therapy for refractory or relapsed patients with Hodgkin Lymphoma and leads to long-term cure in approximately 50% of patients. However, patients refractory to initial treatment have a poor prognosis, even with high-dose chemotherapy and ASCT. Similar to the situation after first-line treatment, the prognosis of patients with refractory disease after ASCT is inferior to the prognosis of patients with later relapse. Altogether, cure rate in Hodgkin Lymphoma decreases dramatically once a patient becomes refractory to treatment, both, after first and after second-line treatment. In this review, we will discuss current and emerging new treatment strategies for the prevention and treatment of refractory Hodgkin Lymphoma.
DEFINITION AND PROGNOSIS OF REFRACTORY HODGKIN LYMPHOMA
Today, there is a widely accepted definition of refractory Hodgkin Lymphoma allowing for the comparison of different trials and analyses.
synonymously. In the narrow sense, refractory disease is defined as failure to achieve a complete remission. However, the definition of refractory Hodgkin Lymphoma usually also includes patients with very early relapse during the first 3 months after the end of treatment. This 3 months' timeframe has been selected arbitrarily, but several analyses have shown that patients with an early relapse have a particularly poor prognosis, similar to patients who never achieve a complete remission. The observation that the duration of remission has a marked effect on the ability of patients to respond to subsequent salvage treatment dates back to 1979 [1] . This finding was later confirmed in a large analysis with 422 patients registered in the German Hodgkin Study Group (GHSG) database [2] . Patients with early (<12-month) and late relapse (12-month) had a 4-year overall survival (OS) of 44 and 72%, respectively. This difference in outcome between early and late relapsed patients is also present when only patients treated with high-dose chemotherapy and ASCT were analysed [2] [3] [4] . The prognosis of patients with primary refractory disease is particularly poor, as demonstrated in a large prospective multicentre trial with 102 patients receiving highdose chemotherapy and ASCT ( Fig. 1 ) [5] . Apart from primary refractory disease after first-line treatment, patients can also suffer from refractory disease after second-line therapy.
Refractory Hodgkin Lymphoma after disease recurrence
The prognosis of patients with Hodgkin Lymphoma with disease recurrence after high-dose chemotherapy and ASCT is poor. Data on this small group of patients are however limited and no established risk factors have been identified so far. A retrospective single-centre analysis of 71 patients relapsing after ASCT found primary refractory disease and relapse within 6 months as significant risk factors in multivariate analyses [6] . More recently, the first large multicentre analysis on patients with refractory or relapsed Hodgkin Lymphoma after ASCT evaluated 126 patients with Hodgkin Lymphoma [7 & ]. In line with findings from first-line therapy, refractory disease at ASCT and disease-free interval less than 12 months after ASCT had a significantly adverse effect on OS. Patients with zero or one of the risk factors interval of less than 12 months from first ASCT to relapse, presence of B-symptoms, and pre-ASCT disease refractoriness had a median survival of 70 months as compared with 17 months in those with two or three factors. In summary,
KEY POINTS
Patients with primary refractory Hodgkin Lymphoma and patients who become refractory in the course of the disease have a poor prognosis.
Intensified first-line regimens can reduce the proportion of primary refractory patients.
Tandem autologous transplant and maintenance therapy are being evaluated for patients with primary refractory disease.
New drugs such as brentuximab vedotin seem to be useful in the treatment and prevention of refractory Hodgkin Lymphoma and are currently being evaluated in combination with conventional chemotherapy and as a bridge to allogeneic transplant. Lymphoma similar to the situation in patients with primary refractory disease, the occurrence of refractory disease at second-line treatment clearly worsens the outcome.
PREVENTION OF REFRACTORY HODGKIN LYMPHOMA
Given the poor prognosis of patients with primary refractory Hodgkin Lymphoma, several strategies aimed at reducing the number of these patients.
In addition, different treatment approaches were followed to overcome the poor prognosis of patients who became refractory to treatment at relapse.
Prevention of refractory Hodgkin Lymphoma with first-line therapy
The cure rates with combined modality treatment in early favourable Hodgkin Lymphoma are excellent with a 5-year progression-free survival (PFS) of more than 90% and a rate of refractory disease of less than 1%. The GHSG HD10 trial has shown that reduced treatment intensity with two cycles of ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) followed by 20 Gy involved field radiotherapy (IFRT) has no negative impact on long-term outcome [8] . However, the situation is different in early unfavourable and advanced disease wherein more patients suffer from primary refractory Hodgkin Lymphoma or become refractory later during the course of their disease. The standard treatment for early unfavourable Hodgkin Lymphoma is four cycles of chemotherapy followed by 30-Gy IFRT. With ABVD as chemotherapy, approximately 80% of patients experience long-term tumour control, which is not satisfying when compared with results in early favourable Hodgkin Lymphoma [8] . The GHSG therefore performed the HD14 trial comparing the standard of four cycles of ABVD with an intensified chemotherapy regimen consisting of two cycles of BEACOPP escalated (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone, BEACOPPesc) followed by two cycles of ABVD (2 þ 2) [9 & ]; all patients received 30-Gy IFRT after chemotherapy. In the final analysis recently reported, rates of progressive disease and relapses were significantly reduced with the intensified 2 þ 2 regimen. PFS at 5 years was 89.1% in the standard arm and 95.4% with intensified treatment (P < 0.001). Although the intensified 2 þ 2 strategy was successful in reducing the number of refractory and relapsing patients, the OS was not significantly different so far with a median followup of 43 months. Longer follow-up is thus needed to see whether the lower number of recurrences with 2 þ 2 will translate into a survival benefit.
There is no generally accepted standard for the treatment of advanced Hodgkin Lymphoma, and both ABVD [10] and BEACOPPesc [11] are currently being used. Although clearly more effective in tumour control, there has been some concern about the more severe effects of eight cycles of BEACOPPesc when compared with ABVD. To reduce treatment-related toxicity for patients with advanced Hodgkin Lymphoma, the GHSG performed the HD15 study that was recently published [12 && ]. Eight cycles of BEACOPPesc were compared with two less intensive regimens in 2126 patients: six cycles of BEACOPPesc or eight cycles of a timeintensified baseline-dose BEACOPP variant given in 14-day intervals. Surprisingly, six cycles of BEACOPPesc were not only noninferior but even significantly superior to eight cycles, both in terms of PFS and OS (90.3 versus 85.6% and 95.3 versus 91.9% at 5 years, respectively). After six cycles of BEACOPPesc followed by PET-adapted radiotherapy, the complete remission rate was 94.2% and the proportion of primary progressive patients was 1.8%. These are the best results that have ever been reported in a large randomized trial for advanced Hodgkin Lymphoma. No randomized trial comparing six cycles of BEACOPPesc and ABVD has thus far been performed; however, in view of this lack of direct evidence, a network analysis comparing BEACOPPesc and ABVD was recently conducted [13] . Data from 10 011 patients treated with 12 different chemotherapy regimens including ABVD and different BEACOPP variants were pooled using network meta-analysis. Direct comparisons within trials were combined with indirect evidence from other trials by using a Bayesian random-effects model. Six cycles of BEACOPPesc were associated with the lowest risk for death of any cause. Assuming a 5-year survival rate of 89% for ABVD, this would result in a 5-year survival benefit of 7% for six cycles of BEACOPPesc. This analysis provides the currently best available evidence on OS of different initial treatment strategies for advanced stage Hodgkin Lymphoma and the results are in line with the hypothesis that the reduction of refractory Hodgkin Lymphoma by intensifying first-line therapy improves OS.
Apart from optimization of conventional combined modality treatment, the anti-CD30 antibody drug conjugate brentuximab vedotin is currently being evaluated in first-line trials for advanced Hodgkin Lymphoma. This drug has demonstrated an impressive response rate as a single agent in patients with relapsed or refractory Hodgkin Lymphoma [14,15 && ]. As the combination of brentuximab vedotin and AVD has been found well tolerated and effective, an international randomized phase III study comparing standard ABVD with brentuximab vedotin and AVD in advanced Hodgkin Lymphoma is currently enrolling. Similarly, the GHSG is currently comparing two new BEACOPP variants in a multicentre phase II trial for patients with advanced Hodgkin Lymphoma (Fig. 2) . This trial aims at further detoxifying BEACOPPesc while maintaining the high tumour control rates. To this end, brentuximab vedotin is combined with BEACOPPesc and the most toxic drugs of the BEACOPPesc regimen are either dose reduced, replaced by other drugs or omitted. This results in the two 'Targeted BEACOPP' regimens BRECAPP (brentuximab vedotin, etoposide, cycylophosphamide, adriamycin, procarbazine, prednisone) and BRECADD (brentuximab vedotin, etoposide, cyclophosphamide, adriamycin, dacarbazine, dexamethasone). Given the high singleagent activity of brentuximab vedotin in relapsed or refractory Hodgkin Lymphoma, the new ABVD or BEACOPPesc-based combinations will hopefully further reduce the proportion of patients with primary refractory disease.
TREATMENT OF REFRACTORY HODGKIN LYMPHOMA
Tandem autologous transplant is a potential strategy to improve the prognosis of patients with Hodgkin Lymphoma with primary refractory disease. In the French H96 prospective multicentre trial [16] , 150 high-risk patients (primary refractory disease or two or more risk factors at first relapse) were assigned to tandem ASCT. In the intent-totreat analysis, the respective 5-year freedom from second failure and OS estimates were 46 and 57%, with similar outcomes in primary refractory and high-risk relapsed patients. The was reported who had relapsed or refractory Hodgkin Lymphoma achieving complete remission (PET negative) or partial remission (PR) (PET positive) after salvage chemotherapy; these patients underwent single or tandem ASCT [17] . Outcomes were significantly better in patients with negative PET than in patients who were PET positive after salvage with PFS and OS rates of 79 versus 23% and 90 versus 55%, respectively. In the PET-positive subgroup, tandem transplant improved 5-year PFS from 0 to 43% (P ¼ 0.034) compared with single ASCT. These results are in line with the findings of the H96 trial and suggest a role of tandem highdose chemotherapy in overcoming refractory Hodgkin Lymphoma. Another strategy to improve the prognosis of primary refractory patients with Hodgkin Lymphoma is currently being evaluated in the international multicentre, prospective, randomized, double-blind phase III AETHERA trial. Patients with at least one of three risk factors (refractory Hodgkin Lymphoma, early relapse or extranodal involvement at the time of pre-ASCT relapse) received brentuximab vedotin or placebo over 16 cycles at 3-week intervals as maintenance after ASCT. The trial has completed enrolment in 2012 and first results are awaited for 2014.
New drugs in refractory Hodgkin Lymphoma
In a phase II multicentre trial of single-agent brentuximab vedotin in patients with recurrence after ASCT, 75% of patients obtained PR and complete remission with 34% complete remission [15 && ]. Of note, 71% of patients in the trial were refractory to prior treatments and no correlation between disease status before therapy (relapsed versus refractory) and response could be observed. This demonstrates the high activity of brentuximab vedotin even in chemorefractory patients. Importantly, the median PFS for patients who achieved a complete remission and did not receive an allogeneic transplant was 21.7 months, indicating that a subset of patients with complete remission after brentuximab vedotin achieve long-term remissions or perhaps even cure. These data are far superior to what can be achieved with conventional chemotherapy combinations.
Apart from brentuximab vedotin, other drugs such as bendamustin [18] and everolimus [19] have also shown promising results in refractory patients.
Allogeneic transplant for refractory Hodgkin Lymphoma
Although allogeneic transplant after myeloablative conditioning led to poor results because of the exceedingly high nonrelapse mortality [20, 21] , several retrospective analyses have suggested that dose-reduced allogeneic transplant (RIC-allo) could be an option for patients with Hodgkin Lymphoma relapsing after ASCT. However, allogeneic transplant alone does not seem to be sufficient to overcome refractory disease. According to retrospective analyses, patients with refractory disease before RIC-allo have a dismal prognosis [22, 23] . Obviously, the prerequisite for a successful allogeneic transplant is the induction of at least a very good PR before transplant. Recently, the largest multicentre phase 2 prospective clinical trial of RIC-allo in relapsed or refractory Hodgkin Lymphoma was reported so far [24 && ]. Ninety-two patients were recruited and 86% had failed prior ASCT. Fifty patients (67%) were allografted with chemosensitive disease (at least PR) and 28 (33%) with chemoresistant disease (defined as SD in this trial). The estimated PFS rate for the allografted population was 48% at 1 year and 24% at 4 years ( Fig. 3) . Chemosensitivity was the most important prognostic factor (hazard ratio 2.3; P ¼ 0.001). Patients allografted in complete remission had the best outcome with PFS rates at 1 and 4 years of 70 and 50%, respectively. After a median follow-up for the surviving patients of 48 months, 33 patients in the allografted population were alive (43%). The estimated OS rates were 71 and 43% at 1 and 4 years, respectively. Refractory disease and poor performance status were associated with a significantly poorer OS (hazard ratio 1.9, P ¼ 0.001 and hazard ratio 2.5, P ¼ 0.01, respectively). This prospective trial clearly demonstrates that patients with Hodgkin Lymphoma refractory to treatment should not be offered RIC-allo. In view of the high proportion of patients refractory to salvage chemotherapy after post-ASCT relapse, new strategies are thus urgently needed.
Lately, two retrospective analyses reported that brentuximab vedotin provides a potential bridge to allogeneic transplant in patients refractory to conventional salvage therapy [25 & ,26] . Best responses were seen after four cycles indicating that allogeneic transplant could be conducted early after the first assessment indicating response to brentuximab vedotin. In view of the moderate PFS achieved with RIC-allo in patients with Hodgkin Lymphoma relapsing after ASCT on the one hand and the longterm remissions observed in some of the patients achieving complete remission with brentuximab vedotin on the other hand, it is currently unclear which patients should undergo RIC-allo. According to several risk factor analyses, the ideal candidate for transplant should be young, have a good performance status and a complete remission before receiving any conditioning regimen [22] . The pros and cons of RIC-allo and brentuximab vedotin only should be thoroughly weighed in each individual case and this open question certainly needs more data from prospective trials before final conclusions. Combination trials with brentuximab vedotin and chemotherapy (e.g. with bendamustin or gemcitabine) in patients with relapsed or refractory Hodgkin Lymphoma are currently enrolling and might lead to further therapeutic options, both as conventional combination therapy and as a bridge to allogeneic transplant.
CONCLUSION
Although Hodgkin Lymphoma is one of the cancers with the highest cure rate, refractory Hodgkin Lymphoma still represents a challenge to modern treatment approaches. Prevention of refractory Hodgkin Lymphoma with intensified first-line therapies has been shown to be successful and new combinations of conventional chemotherapy with targeted drugs will hopefully further reduce the proportion of patients with refractory disease. Once a patient with Hodgkin Lymphoma has become refractory to therapy, the prognosis worsens dramatically. Tandem ASCT has been shown to be effective in selected primary refractory Hodgkin Lymphoma and maintenance with brentuximab vedotin is currently being evaluated. Patients with refractory disease after ASCT have a particular poor prognosis. The prerequisite for a successful RIC-allo in this situation is the achievement of at least partial remission. Brentuximab vedotin has been shown to be an alternative for patients not responding to conventional chemotherapy and has been evaluated as a bridge to allogeneic transplant. Future studies should focus on potential new predictive tools to carefully select patients with post-ASCT recurrence for an allogeneic transplant.
